Skip to main content
TipRanks
Go Ultimate75% OFF

Veradermics, Incorporated (MANE) AI Stock Analysis

91 Followers
MANE

Veradermics, Incorporated

(NYSE:MANE)

Select Model
Rating:54Neutral
Price Target:$138.00â–²(6.43% Upside)
Action:reiterated
Date:11/13/26

The score is constrained primarily by weak financial fundamentals (no revenue, rapidly accelerating losses/cash burn, and a shift to deeply negative equity), which heighten financing risk. Offsetting this, recent clinical-trial corporate events are strongly positive and the technical picture is moderately constructive, while valuation remains challenged due to losses and no dividend support.

Positive Factors
Late-stage clinical validationPositive results across two registration-directed studies provide meaningful clinical validation for VDPHL01. Efficacy, patient-reported benefits, and favorable safety in more than 1,000 participants strengthen the program’s late-stage positioning and could support future regulatory and commercial progress.
Negative Factors
Pre-commercial business modelThe absence of revenue means the company has not yet demonstrated commercial demand or product economics. Widening losses also show that substantial spending is required before potential approval and launch, leaving results dependent on successful clinical and regulatory execution.

Veradermics, Incorporated (MANE) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%300%350%MANE+243.47%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.47B
Dividend Yield
―
Average Volume (3M)
755.78K
Price to Earnings (P/E)
-49.1
Beta (1Y)
0.19
Revenue Growth
―
EPS Growth
-57.61%
Country
US
Employees
51
Sector
General
Sector Strength
55
Industry
Biotechnology

Veradermics, Incorporated Business Overview & Revenue Model

Company Description

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL)...

Veradermics, Incorporated Financial Statement Overview

Summary

Pre-revenue profile with sharply worsening losses and cash burn (net loss ~-$70.0M and operating cash flow ~-$71.6M in 2025). While assets increased and debt is minimal, the swing to deeply negative equity (~-$121.0M in 2025) materially raises funding and balance-sheet risk.

Income Statement

8Very Negative

Balance Sheet

22Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023
Income Statement
Total Revenue0000
Gross Profit0000
EBITDA-99.10M-70.00M-25.90M-16.45M
Net Income-93.58M-70.00M-26.49M-16.49M
Balance Sheet
Total Assets807.22M152.62M59.38M18.46M
Cash, Cash Equivalents and Short-Term Investments798.35M141.86M53.08M16.30M
Total Debt668.00K4,0000786.00K
Total Liabilities10.74M273.63M4.72M3.84M
Stockholders Equity796.47M-121.01M54.66M14.62M
Cash Flow
Free Cash Flow-82.60M-71.63M-23.69M-13.51M
Operating Cash Flow-82.23M-71.60M-23.69M-13.51M
Investing Cash Flow-653.92M-118.86M00
Financing Cash Flow862.65M159.14M60.48M13.89M

Veradermics, Incorporated Risk Analysis

Veradermics, Incorporated disclosed 83 risk factors in its most recent earnings report. Veradermics, Incorporated reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1.We will not receive significant additional funds upon the exercise of the Pre-Funded Warrants sold in the Private Placement.Q2, 2026
2.We will not receive significant additional funds upon the exercise of the Pre-Funded Warrants sold in the Private Placement.Q1, 2026

Veradermics, Incorporated Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

MANE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KNSAKNSA80Outperform$7.57B67.3617.27%―58.19%192.34%
ARQTARQT79Outperform$3.57B121.4414.18%―60.00%―
CAICAI70Outperform$6.61B68.5916.00%―61.48%―
VCELVCEL70Outperform$2.91B86.309.09%―25.30%147.62%
VCYTVCYT70Outperform$1.96B15.309.27%―17.50%311.25%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
MANEMANE54Neutral$5.47B-49.11-19.90%――-57.61%

* General Sector Average

Performance Comparison

0%100%200%300%MANEVCELVCYTKNSAARQTCAIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MANE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MANEVeradermics, Incorporated129.6691.91243.47%
VCELVericel Corporation56.9617.5344.46%
VCYTVeracyte Inc24.33-14.95-38.06%
KNSAKiniksa Pharmaceuticals Ltd. Class A96.3354.93132.68%
ARQTArcutis Biotherapeutics Inc28.262.097.99%
CAICaris Life Sciences, Inc.23.04-0.67-2.83%

Veradermics, Incorporated Corporate Events

Product-Related Announcements

Veradermics Reports Positive Phase 2/3 Hair Loss Trial Results

Positive
Nov 9, 2026

On November 9, 2026, Veradermics reported positive topline results from Part B of Study ‘302,’ a randomized Phase 2/3 trial of VDPHL01 in 519 men with mild-to-moderate pattern hair loss. After six months, placebo participants switched to VDPHL01 for...

Business Operations and StrategyProduct-Related Announcements

Veradermics Reports Strong Phase 3 Hair Loss Results

Positive
Oct 19, 2026

On October 19, 2026, Veradermics reported positive topline results from its Phase 3 Study ‘304’, a multi-center, randomized, placebo-controlled trial of oral VDPHL01 in 536 men with mild-to-moderate pattern hair loss. The extended-release minoxidil p...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026